Please assess the completion status of the following clinical trial:

Trial Title: PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject must be at least 18 years of age.~2. Subject has a Stage II-IV pressure ulcer located in the gluteal, ischial, hip, sacral, coccygeal, and trochanteric, malleolus, or heel area.~3. Pressure ulcer should be present for 4 weeks duration and have a ulcer surface area \> 2cm2~4. If multiple ulcers are present, one ulcer must be identified as the index ulcer.~5. The index ulcer is free from active infection at the time of randomization.~6. Willingness to off-load or pressure redistribute ulcer for duration of enrollment~7. The index ulcer has been offloaded for at least 7 days prior to randomization.~8. The index ulcer must have been present for at least 30 days at time of study enrollment.~9. The index ulcer is separated at least 4 cm from all other ulcers at Study Day -7 and Study Day 0 (post-debridement) and has a margin of intact skin sufficient for anchoring of the required study dressing.~10. Subject has read and signed the IRB/IEC approved Informed Consent Form (ICF) before screening procedures are undertaken.~Exclusion Criteria:~1. Presence of signs and symptoms of infection at the index ulcer site, including but not limited to cellulitis, acute osteomyelitis, excessive exudate, gangrene or deep tissue infection~2. The index ulcer is not free of necrotic tissue and is unable to tolerate debridement~3. Non-enteric or unexplored sinus tract~4. Concomitant conditions that in the judgment of the investigator would make the subject inappropriate for entry to the study~5. Subject has a known sensitivity to porcine materials~6. Subject has a known sensitivity to polyhexamethylenebiguanide (PHMB)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- PuraPly® AM plus Standard of Care (Type: ACTIVE_COMPARATOR): None
- Standard of Care (SOC) for Pressure Ulcers (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).